Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Pancreatic Neoplasms 115Urinary Bladder Neoplasms 56Carcinoma, Non-Small-Cell Lung 53Cholangiocarcinoma 33Biliary Tract Neoplasms 32Neoplasm Metastasis 30Ovarian Neoplasms 29Lymphoma, Large B-Cell, Diffuse 27Breast Neoplasms 25Neoplasms 24Lung Neoplasms 24Carcinoma, Transitional Cell 23Triple Negative Breast Neoplasms 22Nasopharyngeal Carcinoma 21Colorectal Neoplasms 20Non-Muscle Invasive Bladder Neoplasms 19Recurrence 17Fallopian Tube Neoplasms 16Gallbladder Neoplasms 15Sarcoma 13Bile Duct Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Hodgkin Disease 10Lymphoma 9Adenocarcinoma 9Uterine Cervical Neoplasms 8Stomach Neoplasms 7Lymphoma, Non-Hodgkin 7Endometrial Neoplasms 7Nasopharyngeal Neoplasms 6

Interventions

toripalimab 1potassium oxonate 1gimeracil 1apatinib 1Tegafur 1Nivolumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Neoplasms of Digestive Organs × Gemcitabine × 1 year × Clear all
NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

LaNova Medicines Limited

Phase 2 Recruiting
276 enrolled
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡